- Home
- INMB vs ALGS Comparison
INMB vs ALGS Comparison
Compare INMB & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | ALGS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 57.2M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INMB | ALGS |
|---|---|---|
| Price | $1.83 | $10.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.30 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 490.0K | 85.8K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $50,000.00 | ★ $2,646,000.00 |
| Revenue This Year | $173.21 | N/A |
| Revenue Next Year | $12,733.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.05 | N/A |
| 52 Week Low | $1.38 | $3.76 |
| 52 Week High | $11.64 | $46.80 |
Technical Indicators
Market Signals| Indicator | INMB | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 53.71 |
| Support Level | $1.82 | $9.10 |
| Resistance Level | $2.30 | $13.69 |
| Average True Range (ATR) | 0.17 | 0.94 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 38.31 | 32.36 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.